Direct-to-patient healthcare company Ro announced an agreement with the National Institute on Aging (NIA) to develop the Registry for Equal Access to Clinical Trials in Alzheimer's Disease (REACT-AD).
Ro will employ its telehealth platform to screen and recruit patients at elevated risk for developing Alzheimer's disease (AD) or other related dementia to join REACT-AD for potential participation...
Months after announcing a $150 million fundraise that boosted its valuation to $7 billion, direct-to-consumer virtual care company Ro is laying off 18% of its workforce.
"While we took steps over the last six months to prepare for a possible downturn, including raising additional capital and narrowing our focus, we came to the unfortunate conclusion that we needed to make more significant changes...
Direct-to-consumer virtual care company Ro has acquired Dadi, a male fertility and sperm-testing startup.
The move comes less than a year after Ro scooped up another reproductive health-focused company, Modern Fertility.
As part of the deal, the virtual care company will retire the Dadi name and launch the Ro Sperm Kit, which allows users to collect samples at home for analysis and storage. The...
Kallyope, which offers a drug-discovery platform focused on developing therapies involving the gut-brain axis, announced it had raised $236 million in a Series D funding round led by Mubadala Investment Company and the Column Group.
Other participants in the round include Alexandria Venture Investments, Bill Gates, Casdin Capital, Euclidean Capital, Illumina Ventures, Lux Capital, Polaris...
Ro is taking bets on the weight loss industry with a $30 million prepaid order of diet pill Plenity. The New York-based company inked a deal with Plenity creator Gelesis in 2019 to offer the product as part of Ro’s virtual care services.
Plenity, which was cleared by the FDA in 2019 as a Class II Medical Device, comes in the form of an ingestible capsule. While users can tap into Ro’s...
Employee morale is low and turnover is high at direct-to-consumer virtual care company Ro, as the company struggles to expand its success beyond erectile dysfunction medication, according to reporting by TechCrunch.
TechCrunch’s anonymous interviews with 10 current and former Ro workers detail employee churn across departments and a frantic pace to launch or acquire new products that then...
Direct-to-consumer virtual care company Ro is rolling out a new mental health platform, dubbed Ro Mind, that will initially focus on generalized anxiety disorder (GAD) and major depressive disorder (MDD). As part of the service, patients will be able to get a prescription for anxiety and depression medications through the platform, if they fit the criteria.
In a blog posting, Ro’s team said that...
This morning, direct-to-consumer virtual health company Ro announced its plans to buy at-home diagnostic company Kit for an undisclosed sum. This marks the company’s second acquisition in two months.
Kit developed a system that allows patients to self-administer an at-home sample collection. Before taking the sample, patients are asked to download the corresponding app, which contains step-by-...
Ro, a direct-to-consumer virtual care company, is strengthening its foothold in women's health with the acquisition of reproductive health company Modern Fertility for an undisclosed sum.
As part of the deal, Modern Fertility's offerings will be offered via Ro's primary care platform. Like Ro, Modern Fertility built up a direct-to-consumer virtual health business. However, Modern Fertility offers...
Direct-to-consumer virtual care and mail-order prescription startup Ro is adding to its already impressive fundraising haul with a fresh $500 million investment headed by prior backers General Catalyst, FirstMark Capital and TQ Ventures, the company announced this morning.
SignalFire Torch and BoxGroup also returned to participate in the Series D round, as did new investors Altimeter, Baupost,...
